Generate Biomedicines Inc (NASDAQ:GENB - Free Report) - Research analysts at HC Wainwright dropped their FY2026 earnings estimates for Generate Biomedicines in a research report issued on Friday, November 13th. HC Wainwright analyst M. Kapoor now expects that the company will post earnings per share of ($2.46) for the year, down from their previous estimate of ($2.16). HC Wainwright currently has a "Buy" rating on the stock. The consensus estimate for Generate Biomedicines' current full-year earnings is ($2.29) per share. HC Wainwright also issued estimates for Generate Biomedicines' Q4 2026 earnings at ($0.69) EPS, Q1 2027 earnings at ($0.71) EPS, Q2 2027 earnings at ($0.63) EPS, Q3 2027 earnings at ($0.63) EPS, Q4 2027 earnings at ($0.63) EPS and FY2027 earnings at ($2.60) EPS.
GENB has been the subject of a number of other reports. Weiss Ratings lowered Generate Biomedicines from a "sell (d+)" rating to a "sell (d)" rating in a research note on Monday. Wall Street Zen downgraded shares of Generate Biomedicines from a "hold" rating to a "sell" rating in a research note on Saturday, October 17th. Six analysts have rated the stock with a Buy rating, one has issued a Hold rating and one has assigned a Sell rating to the stock. According to data from MarketBeat, the stock presently has an average rating of "Moderate Buy" and an average target price of $26.40.
View Our Latest Analysis on GENB
Generate Biomedicines Stock Performance
Shares of GENB opened at $10.49 on Tuesday. Generate Biomedicines has a 12-month low of $10.38 and a 12-month high of $22.67. The stock's 50-day moving average price is $14.23 and its 200 day moving average price is $14.09.
Generate Biomedicines (NASDAQ:GENB - Get Free Report) last announced its earnings results on Thursday, November 12th. The company reported ($0.68) earnings per share (EPS) for the quarter, missing analysts' consensus estimates of ($0.50) by ($0.18). The company had revenue of $4.22 million for the quarter.
Institutional Investors Weigh In On Generate Biomedicines
Several large investors have recently made changes to their positions in the company. Susquehanna International Group LLP acquired a new stake in shares of Generate Biomedicines during the 2nd quarter worth about $196,000. AXQ Capital LP bought a new position in Generate Biomedicines during the 2nd quarter valued at about $218,000. Summa Corp. acquired a new position in Generate Biomedicines in the third quarter valued at about $250,000. Magnus Financial Group LLC boosted its position in Generate Biomedicines by 39.4% in the third quarter. Magnus Financial Group LLC now owns 21,750 shares of the company's stock valued at $327,000 after buying an additional 6,150 shares in the last quarter. Finally, Squarepoint Ops LLC bought a new stake in Generate Biomedicines during the second quarter worth about $530,000.
Generate Biomedicines Company Profile
(
Get Free Report)
Generate Biomedicines is a biotechnology company that uses generative artificial intelligence and experimental biology to design and develop medicines. Founded in 2018 by Flagship Pioneering, the company is based in Somerville, Massachusetts. Its platform is designed to create new proteins with potential therapeutic applications, including antibodies and other biologic medicines. Generate is advancing a drug-development pipeline across areas such as immunology and oncology; one of its candidates, GB-0895, is being developed for asthma.
Recommended Stories

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.
Before you consider Generate Biomedicines, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Generate Biomedicines wasn't on the list.
While Generate Biomedicines currently has a Moderate Buy rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
Nuclear energy is entering a new growth cycle as rising power demand, expanding data centers, and renewed policy support bring the sector back into focus. After strong gains in recent years, the most impactful phase of nuclear investment may still be ahead. This report highlights seven nuclear energy stocks positioned across the value chain—combining near-term revenue with long-term upside as next-generation technologies scale. Click the link below to unlock the full list.
Get This Free Report
Continue following MarketBeat
Add MarketBeat as your preferred source on Google to see our latest stories in your feed.
Like this article? Share it with a colleague.
Link copied to clipboard.